Healthcare company Novo Nordisk reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for Fiasp (insulin aspart injection) 100 u/ml for use as a new mealtime insulin option for children with diabetes.
Fiasp, which is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, is administered at the beginning of a meal or within 20 minutes after starting a meal. It is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, added the company.
According to the company, Fias is now available for use in children and adults in three different dosing options: multiple daily injections (MDI), continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
This US FDA approval of Fiasp for paediatric use was based on data from the company's onset 7, a 26-week, phase 3b, partially double-blind, basal-bolus, treat-to-target trial, which investigated the efficacy and safety of Fiasp compared with conventional insulin aspart in 777 children with type 1 diabetes, one of the most common chronic conditions diagnosed in childhood, with nearly 18,000 new cases each year.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes